Introduction
============

Aging is a fundamental biological process accompanied by alterations in the regulatory activities performed by the endocrine system, including the thyroid gland ([@b1-ol-0-0-11530]). On the other hand, with aging, the prevalence of hypo- and hyperthyroidism increases ([@b2-ol-0-0-11530]). Both hypo- and hyperpituitarism are believed to affect longevity ([@b3-ol-0-0-11530]). Defining a physiological norm for the thyroid hormones is complicated in the elderly by the gradual resetting of the hypothalamic-pituitary-thyroid axis, which leads to increased levels of thyroid stimulating hormone ([@b4-ol-0-0-11530]).

The prevalence of thyroid neoplasms is increased in the elderly; these tumors are more aggressive in men than in women ([@b5-ol-0-0-11530]). The mortality rate of thyroid cancer (TC) gradually increases with age, from the ages of 40--45 ([@b6-ol-0-0-11530]). Notably, young survivors of TC have increased risks for other aging-related diseases, including diabetes, disorders of lipid metabolism, eye disorders, ear conditions and diseases of the musculoskeletal system and connective tissue ([@b7-ol-0-0-11530]). A majority of TC arise from the epithelial elements of the gland, including thyrocytes and follicular cells. The classification of thyroid tumors into two major groups, differentiated (including papillary, follicular, and medullary) or undifferentiated (anaplastic) carcinoma, based on clinical features and morphology was supported by advances in molecular studies ([@b8-ol-0-0-11530]).

Importantly, a recent study on DNA methylation and histone modification patterns in \>2,000 tumors collected from patients of various ages revealed that most tumor types did not demonstrate age-associated changes in DNA methylation ([@b9-ol-0-0-11530]), which is in agreement with the theory that the epigenetic clock in cancer cells is reprogrammed ([@b9-ol-0-0-11530]). Remarkably, this theory does not hold for thyroid tumors, which displayed age-associated differential methylation of CpGs ([@b9-ol-0-0-11530]). In fact, age at diagnosis serves as a strong indicator of prognosis in TC, particularly in well-differentiated tumors ([@b10-ol-0-0-11530],[@b11-ol-0-0-11530]), with an order of magnitude difference in hazard of death from cancer between the youngest and oldest cohorts. It is also of note that thyroid tissue displays the lowest level of DNA methylation changes in cancer and one of the lowest with aging ([@b9-ol-0-0-11530]).

Overall, previous studies indicate the presence of an association between thyroid carcinogenesis and aging. The present study explored whether genes that promote aging may also play a role in the development of TC, Therefore, besides the identification of previously identified common genes, those that are known to be associated with aging but not with TC are worthy of further study. A mega-analysis of thyroid cancer datasets obtained from Gene Expression Omnibus (GEO) identified two genes, *TNFRSF12A* and *CHI3L1*, as likely contributors to both the process of aging and the thyroid carcinogenesis.

Materials and methods
=====================

### Study workflow

The workflow was organized as follows. Firstly, the large-scale literature-based mining effort for thyroid cancer (TC)- and aging-associated gene sets was undertaken; these gene sets were compared. For each gene from the list implicated in aging alone, a mega-analysis was conducted in 16 publicly available expression datasets retrieved from GEO. For genes that showed significant change in expression across analyzed datasets, functional pathway analysis and protein-protein interaction (PPI) by co-expression analysis were conducted, then conclusions on their pathogenic significance in TC were made.

### Literature-based relation data

Relation data for both aging and TC were extracted and analyzed using Pathway Studio ([www.pathwaystudio.com](www.pathwaystudio.com)), and the results were downloaded into a genetic database Aging_TC, hosted at <http://database.gousinfo.com>. The downloadable format of the database was available at <http://gousinfo.com/database/Data_Genetic/Aging_TC.xlsx>, with different section of the results presented in different worksheets (e.g., age-specific genes were presented in workseheet 'Aging_alone genes'). In this study, we refered to these worksheets in the form of Aging_TC→'worksheet name'. Beside the list of analyzed genes (Aging_TC→Aging_alone genes, Aging_TC→TC_alone genes, and Aging_TC→Common genes), supporting references for each disease-gene relation are presented (Aging_TC→Ref for Aging_alone genes, Aging_TC→Ref for TC_alone genes, and Aging_TC→Ref for Common genes), including titles of the references and the sentences describing identified disease-gene relationships. The information could be used to locate a detailed description of an association of a candidate gene with aging and/or TC. Please refer to Aging_TC→DataNote for the decryption of each worksheet.

### Data selection for mega-analysis

The relevant expression datasets available at GEO (<https://www.ncbi.nlm.nih.gov/geo/>) were retrieved with the keyword 'thyroid cancer' (n=91). The following criteria were applied: i) Organism, *Homo sapiens*; ii) data type, RNA expression; iii) sample size, ≥10; and iv) the studies were performed according to case-control design. A total of 16 datasets remained available for the mega-analysis.

### Mega-analysis models

To discern the effect sizes of the selected genes in a case vs. control expression comparison, both fixed-effect and random-effects models were employed. The expression log fold change (LFC) was used as the effect size. The results derived from both models were compared. In order to assess the variance within and between different studies, the heterogeneity of the mega-analysis was analyzed. In the case that total variance Q was equal to or smaller than the expected between-study variance df, the statistic ISq=100% × (Q-df)/Q was set as 0, and a fixed-effect model was selected for the mega-analysis. Otherwise, a random-effects model was selected. The genes with significant effects were identified according to the following criteria: P\<1×10^−7^ and effect size (LFC) \>1 or \<-1.

### Multiple linear regression analysis

A multiple linear regression (MLR) model was employed to study the possible influence of three factors on the changes in gene expression in TC: Sample size, population region, and study age. P-values and 95% confidence interval (CI) were reported for each of the factors.

### Pathway analysis

For the set of genes identified through expression mega-analysis described above, a functional pathway analysis was conducted with an aim to identify potential biological associations between the selected genes and the TC. The analysis was performed using the 'Shortest Path' module of Pathway Studio ([www.pathwaystudio.com](www.pathwaystudio.com)).

### Co-expression analysis

For each pair of the genes/proteins identified in the pathway analysis, a study of their co-expression was executed. The purpose of this analysis was to identify possible protein-protein interaction (PPI) of the proteins involved. The Fisher\'s Z was employed as the effect size for the mega-analysis, as shown in the equation below:
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All co-expression associations with P-value \<1×10^−4^ and Fisher\'s Z-value ≥0.3 or ≤-0.3 were identified as significant, and then presented as a Cytoscape-imaged PPI network.

Results
=======

### Genes commonly affected by the process of aging and by the carcinogenesis in the thyroid gland

The curated Aging_TC database identified 262 genes with substantially increased expression or activity with aging (supported by 1,495 scientific references) and 816 genes associated with the pathogenesis of TC (supported by 4,169 references). A total of 63 genes were identified to be involved in both aging and TC (right tail Fisher\'s exact test, P=3.82×10^−35^; [Fig. S1](#SD1-ol-0-0-11530){ref-type="supplementary-material"}), which accounts for about a quarter of the genes associated with aging (24.05%). The descriptions of these 63 genes are presented in [Table I](#tI-ol-0-0-11530){ref-type="table"}. Further information on these genes was also provided in Aging_TC→Common genes and Aging_TC→Ref for common genes.

In order to assess the functional profile of the 63 genes associated with both aging and TC, a gene set enrichment analysis (GSEA) against the GO and Pathway Studio Ontology was conducted. The GSEA showed that these common genes were mainly involved in the protein kinase domain, cell proliferation, tissue development, gland development and response to hormone processes. Specifically, this analysis uncovered a total of three pathways/gene sets associated with cell apoptosis (26 unique genes) and 2 pathways/gene sets associated with cell growth proliferation (25 unique genes). A bar plot of the 39 pathways and enriched genes out of the 63 common genes are presented in [Fig. S2](#SD1-ol-0-0-11530){ref-type="supplementary-material"}.

### Gene expression analysis result

Although there was a significant overlap between aging- and TC-associated gene sets (n=63; P=3.82×10^−35^), a majority of the aging-associated genes (n=199 or 75.95%) have not been yet implicated in the pathogenesis of TC. Therefore, the association between each of these 199 genes with TC was examined, using 16 gene expression datasets shown in [Table II](#tII-ol-0-0-11530){ref-type="table"} ([@b12-ol-0-0-11530]--[@b26-ol-0-0-11530]). The detailed description of the results is presented in Aging_TC→Mega-analysis. The significance of association criteria (P\<1×10^−7^ and absolute LFC\>1) was met by two genes and presented in [Table III](#tIII-ol-0-0-11530){ref-type="table"}.

For each gene, a LFC was estimated from the majority of the 16 studies (a total of 16 and 14 studies for *CHI3L1* and *TNFRSF12A*, respectively). As shown in [Fig. 1](#f1-ol-0-0-11530){ref-type="fig"}, the mRNA expression levels of *TNFRSF12A* demonstrated strong between-study variances (ISq=54.07% and Q test P=8.2×10^−3^); therefore, the random-effects model was selected for the mega-analysis. In contrast, no significant between-study variance was observed for the gene *CHI3L1* (ISq=14.73% and Q test P\>0.28); therefore, the fixed-effect model was selected for analysis of its mRNA expression levels. This identified the sample population region (country) as a significant factor that influences the LFC of both genes in the case of TC (P\<3.24×10^−4^; [Table III](#tIII-ol-0-0-11530){ref-type="table"}).

### Functional pathway analysis

According to the *de novo* approach selected for the identification of novel TC-associated genes, no prior direct link to the pathogenesis of TC were known. However, Pathway Studio-guided 'shortest path analysis' revealed plausible associations of *CHI3L1* and *TNFRSF12A* genes with TC, with a set of common interactions ([Fig. 2A](#f2-ol-0-0-11530){ref-type="fig"}).

Using Pathway Studio, the 'shortest path' analysis was conducted to identify associated genes that link *CHI3L1* and *TNFRSF12A*-encoded molecules to the pathogenesis of TC in a unidirectional way. For example, the association between *CHI3L1* and transforming growth factor β1 (TGFB1) in TC was identified. YKL-40, also known as chitinase-3-like protein 1 (*CHI3L1*), is a secreted glycoprotein that binds to interleukin-13 receptor α2 (IL-13Rα2) and subsequently stimulates the production of TGF-β1 ([@b27-ol-0-0-11530]), a key molecule in thyroid carcinogenesis and considered as a new prognostic and therapeutic target for TC ([@b28-ol-0-0-11530],[@b29-ol-0-0-11530]). The details for all other associations are presented in [Fig. 2A](#f2-ol-0-0-11530){ref-type="fig"}, and are described in Aging_TC→TC-2Genes_potential pathways. This reference information included the type of association, the amount of underlying supporting references, and the relevant sentences where these relationships were identified and described. The shortest pathway analysis was conducted using the Pathway Studio ([www.pathwaystudio.com](www.pathwaystudio.com)). All TC-associated genes reported in the shortest pathway analysis were employed in the identification of the TC-associated genes.

In order to confirm the associations depicted in [Fig. 2A](#f2-ol-0-0-11530){ref-type="fig"}, another mega-analysis was conducted using 16 datasets, with the purpose to evaluate the co-expression pattern of mRNAs encoded by *CHI3L1* and *TNFRSF12A*, and 31 genes that link the two genes with TC. The association between *CHI3L1* and *TNFRSF12A* and 13 of the 31 genes presented in [Fig. 2A](#f2-ol-0-0-11530){ref-type="fig"} was validated (P\<0.005; [Fig. 2B](#f2-ol-0-0-11530){ref-type="fig"}). Please refer to Aging_TC→MetaResults_ShortestPath for the detailed description of the associations presented in [Fig. 2B](#f2-ol-0-0-11530){ref-type="fig"}. In addition, a PPI network connecting the products of *CHI3L1* and *TNFRSF12A* and the 'bridge' genes (n=31) were generated using Cytoscape ([Fig. 3](#f3-ol-0-0-11530){ref-type="fig"}). The detailed information of the mega-analysis for the co-expression was presented in Aging-TC→PPI, including a list of the genes (nodes) of the PPI network, and the mega-analysis results for each pair of gene-gene correlation.

Discussion
==========

The present study aimed to identify novel molecular pathways, which connect the process of aging and the development of TC. By removing all known associations between curated sets of genes involved in aging and TC, uncovered aging-associated contributors to TC were identified. According to the pre-selected significance of association criteria (P\<1×10^−7^ and abs(LFC)\>1), two aging-associated genes, *TNFRSF12A* and *CHI3L1*, were found to be involved in the development of TC.

The role of *TNFRSF12A* and *CHI3L1* in the aging-associated disease is well described, whereas no apparent connections to the malignant processes in the thyroid were reported thus far. *TNFRSF12A* encodes for an exclusive receptor for tumor necrosis factor-related weak inducer of apoptosis (*TWEAK*), an interacting pair of molecules involved in age-associated pathological changes in skeletal muscle and other organs ([@b30-ol-0-0-11530]--[@b32-ol-0-0-11530]). *CHI3L1* encodes for YKL-40, a glycoprotein upregulated in a variety of inflammatory conditions commonly found in the elderly, including chronic obstructive pulmonary disease and neurodegenerative diseases ([@b33-ol-0-0-11530],[@b34-ol-0-0-11530]).

Employing a Pathway Studio-guided 'shortest path analysis' revealed plausible associations of *TNFRSF12A* and *CHI3L1* with TC, simultaneously highlighting a set of common interactors that included the signaling molecules *AKT1, RAC1, MAPK1* and the soluble proteins *TNF-α*, albumin, *TIMP1* and *MMP9*.

Among these, the association of *TNFRSF12A* and *CHI3L1* with *AKT1* was notable, as this molecule was both overexpressed and over-activated in TC ([@b35-ol-0-0-11530]). Moreover, increased Akt signaling led to increased Bcl-2 promoter activity and cell survival ([@b36-ol-0-0-11530]). The interaction between *TNFRSF12A* and *TWEAK* also positively regulated pro-survival molecules of the *Bcl2* family ([@b37-ol-0-0-11530],[@b38-ol-0-0-11530]), and, therefore augmented the pro-survival signal of *AKT1* ([@b39-ol-0-0-11530]).

Among the soluble molecules, angiogenic matrix metalloproteinase (*MMP)9* was found to be associated with *TNFRSF12A* and *CHI3L1*, which participates in follicular TC cell invasion ([@b40-ol-0-0-11530]). *TIMP-1*, acts as an inhibitor for *MMP9* expression that is often co-expressed with this molecule in thyroid tumors and serves as a reliable surrogate marker for BRAF-mutated status and likely aggressiveness ([@b41-ol-0-0-11530]). Notably, *TIMP*−1 serves as a prominent PPI hub gene in the Cytoscape network built upon co-expression of *TNFRSF12A* and *CHI3L1*, along with *LGALS3*, a specific biomarker of well-differentiated thyroid carcinomas ([@b42-ol-0-0-11530]), *CXCL16*, which mediated the involvement of macrophages in the invasion of papillary TCs ([@b43-ol-0-0-11530]) and fibronectin, an EMT biomarker which promoted migration and invasion of papillary thyroid cancers ([@b44-ol-0-0-11530]).

Importantly, many of the molecules discussed above were upregulated in response to hypoxia ([@b45-ol-0-0-11530]), or stimulated the expression of key mediators of the antihypoxic response ([@b46-ol-0-0-11530]), or both ([@b47-ol-0-0-11530],[@b48-ol-0-0-11530]). Both *HIF-1α* and *HIF-2α* were reported to be expressed in TC ([@b49-ol-0-0-11530]). Moreover, a growing evidence points out that hypoxia plays a significant role in the maintenance of thyroid cancer stem cells (CSC) ([@b50-ol-0-0-11530]). General hypoxia due to diminished vascularization is a well-known characteristic of aging tissues, possibly due to endothelial dysfunction as well decreased function of endothelial progenitor cell function ([@b51-ol-0-0-11530],[@b52-ol-0-0-11530]). For more information regarding the hypoxia-gene regulation presented in [Fig. 2A](#f2-ol-0-0-11530){ref-type="fig"}, please refer to Aging_TC→TC_2Genes_potential pathway. Therefore, it can be speculated that the age-dependent increase in hypoxia may also contribute to the increased aggressiveness of TC observed in the elderly ([@b10-ol-0-0-11530],[@b11-ol-0-0-11530]).

The results could be influenced by multiple factors, including sample size and sample source. Considering the fact that the pathology of disease could change with time, the publication date/age was checked in the present study. The MLR analysis showed that country region was a significant factor that could influence the gene expression levels of TC genes, but not the other two factors. Other influencing factors of TC gene activities could include mortality or epigenetics. However, due to be the limitation of the metadata, these factors were not amiable for analysis in the datasets employed in the present study, which would be valuable for future studies.

In conclusion, the present study conducted a functional pathway and co-expression analysis, and mined a set of genes associated with aging. *TNFRSF12A* and *CHI3L1* were identified as previously unrecognized contributors to the development of thyroid tumors, which are known for unusual increase in aggressiveness in the elderly. An analysis of the Cytoscape network built upon co-expression of *TNFRSF12A* and *CHI3L1* points towards tissue hypoxia as a bridging factor, which is common for the pathophysiology of aging and the development of TC.
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![Effect size, 95% CI and weights of the expression levels of *TNFRSF12A* and *CHI3L1*. (A) Mega-analysis results for *CHI3L1*; (B) Mega-analysis results for *TNFRSF12A*. Fixed-effect model and random-effects model were employed for *CHI3L1* and *TNFRSF12A*, respectively. CI, confidence interval.](ol-19-06-3634-g01){#f1-ol-0-0-11530}

![Hypoxia driven interaction network that links *CHI3L1* and *TNFRSF12A* to thyroid cancer. (A) The network generated in Pathway Studio environment ([www.pathwaystudio.com](www.pathwaystudio.com)). Each relation (edge) in the figure has one or more supporting references. (B) Network containing only protein-protein interactions validated by 14 thyroid cancer expression datasets.](ol-19-06-3634-g02){#f2-ol-0-0-11530}

![Protein-protein interaction network generated in Cytoscape for *CHI3L1* and TNFRSF12A and the 'bridge' genes. Each edge represents a significant association (P\<1×10^−4^) between the mRNA expression levels encoded by *CHI3L1* and *TNFRSF12A*. Positive associations are highlighted in red; negative associations are highlighted in blue. A red node represents an overall positive association within the network, whereas a blue node represents an overall negative association. The size of the node represents the centrality of the respective protein. The larger the size, the higher the centrality of the protein. The labels on the edge represent the correction coefficients in terms of Fisher\'s Z-value as derived from the mega-analysis.](ol-19-06-3634-g03){#f3-ol-0-0-11530}

###### 

Common genes associated with aging and thyroid cancer.

  Name         Entrez Gene ID                                                                            Human chromosome position
  ------------ ----------------------------------------------------------------------------------------- ---------------------------
  *SERPINC1*   462;304917;11905                                                                          1q25.1
  *IL17A*      16171;301289;3605                                                                         6p12.2;6p12
  *EDN1*       1906;24323;13614                                                                          6p24.1
  *LCN2*       16819;170496;3934                                                                         9q34.11;9q34
  *PTGS2*      19225;29527;5743                                                                          1q31.1;1q25.2-q25.3
  *HLA-G*      24747;14991;3135                                                                          6p21.3;6p22.1
  *CSF1*       1435;12977;78965                                                                          1p13.3
  *MIF*        4282;17319;81683                                                                          22q11.23
  *PTH*        19226;24694;5741                                                                          11p15.3;11p15.3-p15.1
  *CYP27B1*    1594;13115;114700                                                                         12q14.1
  *CYP24A1*    25279;1591;13081                                                                          20q13;20q13.2
  *HUWE1*      59026;10075                                                                               Xp11.22
  *EIF2AK2*    5610;54287;19106                                                                          2p22-p21;2p22.2
  *PDGFRB*     5159;24629;18596                                                                          5q32;5q33.1
  *APP*        54226;351;11820                                                                           21q21.3
  *HYOU1*      10525;12282;192235                                                                        11q23.1-q23.3;11q23.3
  *EGF*        25313;1950;13645                                                                          4q25
  *TNF*        24835;21926;7124                                                                          6p21.3;6p21.33
  *HMOX1*      15368;3162;24451                                                                          22q12.3;22q13.1
  *MIR21*      406991                                                                                    17q23.1
  *MMP9*       81687;17395;4318                                                                          20q11.2-q13.1;20q13.12
  *FAS*        246097;14102;355                                                                          10q23.31;10q24.1
  *DPP4*       25253;1803;13482                                                                          2q24.3;2q24.2
  *KLK3*       18048;18050;354;13648;16619;16618;16613;16624;16612;16623;16622;13646;16617;16616;16615   19q13.33;19q13.41
  *PROS1*      19128;81750;5627                                                                          3q11.2;3q11.1
  *FASLG*      14103;356;25385                                                                           1q23;1q24.3
  *GPX3*       2878;64317;14778                                                                          5q23;5q33.1
  *ALB*        11657;213;24186                                                                           4q13.3
  *DCN*        1634;13179;29139                                                                          12q21.33
  *B3GAT1*     27087;76898;117108;964                                                                    11q25
  *ADIPOQ*     9370;246253;11450                                                                         3q27;3q27.3
  *ARG2*       11847;29215;384                                                                           14q24.1
  *RUNX3*      12399;156726;864                                                                          1p36.11;1p36
  *PRDX1*      5052;18477;100363379;117254                                                               1p34.1
  *HTRA1*      5654;65164;56213                                                                          10q26.13;10q26.3
  *RCAN1*      54720;1827                                                                                21q22.12
  *CTNNB1*     84353;12387;1499                                                                          3p21;3p22.1
  *BAG3*       9531;29810;293524                                                                         10q25.2-q26.2;10q26.11
  *TGFB1*      21803;7040;59086                                                                          19q13.1;19q13.2
  *TGFA*       24827;21802;7039                                                                          2p13;2p13.3
  *CTSD*       1509;171293;13033                                                                         11p15.5
  *MUC1*       4169;4582                                                                                 1q21;1q22
  *TRAP1*      68015;10131;287069                                                                        16p13.3
  *CDKN1A*     12575;114851;1026                                                                         6p21.2
  *CCNA2*      12428;114494;890                                                                          4q27
  *CCR2*       1231;12772;729230                                                                         3p21.31
  *IL21*       59067;365769;60505                                                                        4q26-q27;4q27
  *BAX*        12028;24887;581                                                                           19q13.33;19q13.3-q13.4
  *IL4*        287287;3565;16189                                                                         5q31.1
  *ENO1*       2023;24333;433182;13806                                                                   1p36.23;1p36.2
  *HGF*        3082;15234;24446                                                                          7q21.11;7q21.1
  *TNFSF10*    246775;22035;8743                                                                         3q26.31;3q26
  *IL6*        24498;3569;16193                                                                          7p15.3;7p21
  *THRA*       7067;81812;21833                                                                          17q11.2;17q21.1
  *ANGPT2*     89805;11601;285                                                                           8p23.1
  *EP300*      170915;2033;328572                                                                        22q13.2
  *GSTM1*      2944;14863;24424                                                                          1p13.3
  *CCL2*       287562;6347;20293                                                                         17q12;17q11.2-q12
  *TXNIP*      117514;56338;10628                                                                        1q21.1
  *GSTT1*      2952                                                                                      22q11.23
  *POSTN*      50706;361945;10631                                                                        13q13.3
  *NQO1*       18104;1728;24314                                                                          16q22.1
  *IL10*       16153;25325;3586                                                                          1q31-q32;1q32.1

###### 

Datasets used for thyroid cancer-aging relation mega-analysis.

  Study                         Dataset GEO ID   Control, n   Case, n   Country     Refs.
  ----------------------------- ---------------- ------------ --------- ----------- -------------------------------------------
  Jarzab *et al*, 2015          GSE35570         51           65        Poland      ([@b12-ol-0-0-11530])
  Rusinek *et al*, 2015         GSE58545         18           27        Poland      ([@b13-ol-0-0-11530])
  Swierniak *et al*, 2015       GSE58689         18           27        Poland      ([@b13-ol-0-0-11530])
  Tarabichi *et al*, 2015       GSE60542         34           33        Belgium     ([@b14-ol-0-0-11530])
  von Roemeling *et al*, 2015   GSE65144         13           12        USA         ([@b15-ol-0-0-11530])
  Versteyhe *et al*, 2013       GSE39156         16           48        Belgium     ([@b16-ol-0-0-11530])
  Pita *et al*, 2013            GSE53157         3            24        Portugal    ([@b17-ol-0-0-11530])
  Tomas *et al*, 2012           GSE29265         20           29        Belgium     N/A
  Tomas *et al*, 2012           GSE33630         45           60        Belgium     ([@b18-ol-0-0-11530],[@b19-ol-0-0-11530])
  Giordano *et al*, 2011        GSE27155         4            95        USA         ([@b20-ol-0-0-11530],[@b21-ol-0-0-11530])
  Yu *et al*, 2008              GSE5364          58           270       Singapore   ([@b22-ol-0-0-11530])
  Fontaine *et al*, 2007        GSE6339          135          48        France      ([@b23-ol-0-0-11530])
  Salvatore *et al*, 2007       GSE9115          4            15        USA         ([@b24-ol-0-0-11530])
  Reyes *et al*, 2006           GSE3678          7            7         USA         N/A
  Vasko *et al*, 2006           GSE6004          4            14        USA         ([@b25-ol-0-0-11530])
  Liyanarachchi *et al*, 2005   GSE3467          9            9         USA         ([@b26-ol-0-0-11530])

N/A, not applicable.

###### 

Significant genes from mega-analysis \[P\<1×10^−7^ and abs(LFC)\>1\] involved in aging and thyroid cancer.

                Mega-analysis results   Multiple linear regression analysis for three factors                                                     
  ------------- ----------------------- ------------------------------------------------------- ------ ------ -------------- ------ ------------- ------
  *CHI3L1*      0                       16                                                      2.88   0.42   5.10×10^−12^   0.24   2.77×10^−4^   0.15
  *TNFRSF12A*   1                       14                                                      1.79   0.33   2.05×10^−8^    0.35   3.24×10^−4^   0.56

LFC, log fold change. STD, standard deviation.

[^1]: Contributed equally
